Floriaan Schmidt

Publications

• Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population
• A machine learning model to aid detection of familial hypercholesterolaemia
• Mendelian randomization for studying the effects of perturbing drug targets [version 2; peer review: 3 approved, 1 approved with reservations]
• Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics
• Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease
• Dementia in the older population is associated with neocortex content of serum amyloid P component
• Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
• Genetic drug target validation using Mendelian randomisation
• Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care setting
• Risk Factors and Prevalence of Dilated Cardiomyopathy in Sub-Saharan Africa: Protocol for a Systematic Review
• Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R
• Low‐Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific
• Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings
• Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins
• The impact of fatty acids biosynthesis on the risk of cardiovascular diseases in Europeans and East Asians: A Mendelian randomization study
• Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases
• Association of Factor V Leiden With Subsequent Atherothrombotic Events
• The median and the mode as robust meta‐analysis estimators in the presence of small‐study effects and outliers
• ANNALS EXPRESS: Establishing reference intervals for triglyceride containing lipoprotein sub-fraction metabolites measured using Nuclear Magnetic Resonance Spectroscopy in a UK population
• Adjustment for index event bias in genome-wide association studies of subsequent events
• Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: A prospective analysis in 11,560 adults
• Lipid lowering and Alzheimer disease risk: A mendelian randomization study
• Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study
• Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins
• Cardiac MRI measures as surrogate outcome for heart failure and atrial fibrillation: a Mendelian randomization analysis
• Risk Factors and Prevalence of Dilated Cardiomyopathy in Sub-Saharan Africa: Protocol for a Systematic Review (Preprint)
• Combining stacked polygenic scores with clinical risk factors improves cardiovascular risk prediction in people with type 2 diabetes
• Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16 126 Participants.
• Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
• Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics
• Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia
• ESTABLISHING REFERENCE INTERVALS FOR TRIGLYCERIDE CONTAINING LIPOPROTEIN SUB-FRACTION METABOLITES MEASURED USING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY IN A UK POPULATION
• Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
• PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
• Association Between Adrenergic Receptor Modulation and the Risk of Heart Failure: A Two-sample Mendelian Randomization Study
• Human Genomics and Drug Development.
• Unravelling the Difference Between Men and Women in Post-CABG Survival
• Prevalence and Disease Expression of Pathogenic and Likely Pathogenic Variants Associated With Inherited Cardiomyopathies in the General Population
• Obesity causes cardiovascular diseases: adding to the weight of evidence
• Evaluating the predictive performance of genetic and non-genetic scores in cardiovascular disease
• Exploring the total and direct effect of 14 triglyceride-containing lipoprotein sub-fraction metabolites and coronary heart disease: A two-sample Mendelian randomisation analysis
• No Clinically Relevant Effect of Heart Rate Increase and Heart Rate Recovery During Exercise on Cardiovascular Disease: A Mendelian Randomization Analysis.
• A cis-Mendelian randomization approach to evaluate genetic support for lipid-modifying drug targets
• Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
• The impact of fatty acids biosynthesis on the risk of cardiovascular diseases in Europeans and east Asians: a Mendelian randomization study
• Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.
• Polygenic scores in disease prediction: evaluation using the relevant performance metrics
• Druggable proteins influencing cardiac structure and function: implications for heart failure therapies and cancer related cardiotoxicity
• Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization
• Mendelian randomization for studying the effects of perturbing drug targets [version 1; peer review: awaiting peer review]
• PCSK9 monoclonal antibodies for the primary and se condary prevention of cardiovascular disease
• Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation study
• Linear regression and the normality assumption.
• Mendelian randomization with Egger pleiotropy correction and weakly informative Bayesian priors.
• Impact of Selection Bias on Estimation of Subsequent Event Risk.
• Association analyses based on false discovery rate implicate new loci for coronary artery disease.
• Genetic drug target validation using Mendelian randomization
• Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
• An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors
• Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
• Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
• Associations Between Measures of Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Cohort Study and Mendelian Randomization Analysis Using the UK Biobank
• PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review)
• Justification of exclusion criteria was underreported in a review of cardiovascular trials.
• Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs.
• PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
• Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis
• Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events
• Subsequent Event Risk in Individuals With Established Coronary Heart Disease
• Triglyceride-Containing Lipoprotein Sub-Fractions and Coronary Heart Disease and Stroke Risk
• Heart failure following myocardial infarction: a cohort study of incidence and prognostic factors in 24 745 patients using linked electronic records
• PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease[protocol]
• Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples
• Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study.
• Comments on 'the use of propensity scores and observational data to estimate randomized controlled trial generalizability bias' by Taylor R. Pressler and Eloise E. Kaizar, Statistics in Medicine 2013.
• Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis
• Tailoring treatments using treatment effect modification
• Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: An individual patient data meta-analysis
• Adjusting for Confounding in Early Postlaunch Settings: Going beyond Logistic Regression Models
• Re: Is the risk difference really a more heterogeneous measure?
• Mendelian Randomisation study of the influence of eGFR on coronary heart disease.
• Comparison of variance estimators for meta-analysis of instrumental variable estimates.
• Adjusting for bias in unblinded randomized controlled trials.
• When drug treatments bias genetic studies: Mediation and interaction
• Performance of polygenic risk scores in screening, prediction, and risk stratification
• Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins on cardiovascular and non-cardiovascular outcomes
• Cardiac MRI to guide heart failure and atrial fibrillation drug discovery: a Mendelian randomization analysis
• Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
• Untargeted metabolomics identifies potential hypertrophic cardiomyopathy biomarkers in carriers of MYBPC3 founder variants
• Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity
• Comparing the effect profile of CETP in individuals of East Asian and European ancestries
• Stacking multiple prediction models to optimise performance in local settings: exemplars in cardiometabolic disease
• Comparing the effect profile of cholesteryl ester transfer protein (CETP) in individuals of East Asian and European ancestries
• Genetic evidence for serum amyloid P component as a drug target for treatment of neurodegenerative disorders
• DCM-PROGRESS: predicting end-stage heart failure in non-ischemic dilated cardiomyopathy patients
• Triangulating evidence from observational and Mendelian randomization studies of ketone bodies for cognitive performance
• Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers
• Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies: Results From a Dutch Multicenter Cohort Study.
• Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants
• Individualized Family Screening for Arrhythmogenic Right Ventricular Cardiomyopathy
• “C1-inhibitor levels and venous thromboembolism: results from a Mendelian randomization study”: reply
• Prospective associations between diet quality, dietary components, and risk of cardiometabolic multimorbidity in older British men
• C1-inhibitor levels and venous thromboembolism: results from a Mendelian randomization study
• Sex-specific Mendelian randomisation to assess the causality of sex differences in the effects of risk factors and treatment: spotlight on hypertension
• Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation
• Identifying and ranking novel independent features for cardiovascular disease prediction in people with type 2 diabetes
• Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity
• Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog.
• Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis
• Prioritising genetic findings for drug target identification and validation
• Integrating urinary and plasma omics to identify markers and therapeutic targets for cardiac disease
• Comparing the drug target effects of Cholesteryl ester transfer protein (CETP) on cardiovascular diseases in East Asian and European populations
• A Machine Learning Model to Aid Detection of Familial Hypercholesterolemia
• Influence of stressful life events and personality traits on PLN cardiomyopathy severity: an exploratory study
• Unraveling the relationships between alpha- and beta-adrenergic modulation and the risk of heart failure
• Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog
• Prospective association of the Mediterranean diet with risk of cardiometabolic multimorbidity in a UK-based cohort: the EPIC-Norfolk study
• Utilizing multimodal AI to improve genetic analyses of cardiovascular traits.
• NMR metabolomic modeling of age and lifespan: A multicohort analysis.